AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Multi-ethnic innovation helps all complexions appear clearer and more uniform
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
The composition of ORAAL is protected by a granted patent in India until November 2033
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
WINLEVI works differently from any other topical acne treatment
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Subscribe To Our Newsletter & Stay Updated